The use of the OncoBEAMTM RAS-CRC assay (a BEAMing panel targeting 34 separate KRAS and NRAS mutations) provided a highly sensitive and accurate detection of RAS mutations, enabling reliable longitudinal monitoring to track the appearance and disappearance of somatic alterations by sampling only plasma-derived cfDNA. Here, KRAS is linked to colorectal carcinoma.